ClinicalTrials.gg
CompletedNCT05887765Updated Sep 18, 2025

Effect of Systematic Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Pediatric Ankle Surgery

A Phase 4 interventional study of Sodium Chloride 0.9% Inj and 0,1mg/kg Dexamethasone in Ankle Disease, Foot Deformities and Foot Diseases, sponsored by Poznan University of Medical Sciences. Completed at 2 sites in Poland. Open to participants aged 3 Months to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Poznan University of Medical Sciences · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
3 Months to 18 Years
Sex
All
01

Study summary

Effect of systematic dexamethasone on the duration of popliteal nerve block after pediatric ankle/foot surgery

Read the detailed description

This study is proposed to explore the effect of systemic dexamethasone on the duration of popliteal nerve block for analgesia after pediatric ankle surgery.

After ankle or foot surgery, children need good analgesia. Peripheral nerve blocks have provided a safe, effective method to control early postoperative pain when symptoms are most severe.

The safety of local anesthesia is particularly important in children due to the much lower toxicity threshold of local anesthetics. The use of an effective adjuvant, such as Dexamethasone, could allow for the use of a higher dilution of local anesthetics while maintaining and enhancing their analgesic effect.

There is multiple research where intravenous and perineural dexamethasone use has been compared in adults. However, there is a huge lack of research regarding children.

In this study, investigators compare different doses of systemic dexamethasone. Before the anesthesia, the patients receive dexamethasone intravenously. Groups 2 and 3 have dexamethasone doses of 0.1mg/kg, and 0.2mg/kg.

The investigator's goal is to find a dexamethasone dose that is as low as possible but at the same time covers the need for good pain relief and fast recovery postoperatively.

02

Conditions studied

  • Ankle Disease
  • Foot Deformities
  • Foot Diseases
  • Cerebral Palsy
03

In context

Foot Deformities

50 studies on the registry are indexed under Foot Deformities; 13 are open to participants now.

This study's enrollment of 90 is above the median of 60 across 26 interventional studies indexed under Foot Deformities.

Browse Foot Deformities studies →

Lead sponsor

Poznan University of Medical Sciences is the lead sponsor of 151 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • children scheduled for ankle/foot surgery
  • body weight > 5kg

Exclusion criteria

Exclusion Criteria:

  • infection at the site of the regional blockade
  • coagulation disorders
  • immunodeficiency
  • ASA= or >4
  • medication in regular use
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    placebo injection

    5ml of 0,9% sodium chloride - before the popliteal nerve block

    Drug: Sodium Chloride 0.9% Inj

  • Active comparator
    0,1mg/kg Dexamethasone

    0,1mg/kg dexamethasone sodium phosphate - before the popliteal nerve block

    Drug: 0,1mg/kg Dexamethasone

  • Active comparator
    0,2mg/kg Dexamethasone

    0,2mg/kg dexamethasone sodium phosphate - before the popliteal nerve block

    Drug: 0,2mg/kg Dexamethasone

Interventions

  • administration of 5ml 0,9% sodium chloride - 30 minutes before the popliteal nerve block

    Also known as: Placebo

  • Drug0,1mg/kg Dexamethasone

    administration of 0,1mg/kg Dexamethasone - 30 minutes before the popliteal nerve block

    Also known as: small dose

  • Drug0,2mg/kg Dexamethasone

    administration of 0,2mg/kg Dexamethasone - 30 minutes before the popliteal nerve block

    Also known as: large dose

06

What researchers measure

Primary outcomes

  1. first need of opiate

    Time after surgery when the patient needs opiate for the first time

    Time frame: 48 hours

Secondary outcomes

  1. Opioid Consumption

    Total opiate consumption after surgery

    Time frame: 48 hours

  2. Pain score

    children \<3years old FLACC score (Face, Legs, Activity, Cry, Consolability) children \>3years old NRS (Numerical Rating Scale)

    Time frame: 4 hours, 8 hours, 12 hours, 16 hours, 18 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 hours, 48 hours after surgery

  3. Blood glucose

    Blood glucose every 24 hour during hospitalization

    Time frame: 24 and 48 hours after surgery

  4. NLR

    Neutrophil-to-lymphocyte ratio

    Time frame: 24 and 48 hours after surgery

  5. PLR

    Platelet-to-lymphocyte ratio

    Time frame: 24 and 48 hours after surgery

  6. Mobilisation

    Toe movement every 4 hours

    Time frame: 4 hours, 8 hours, 12 hours, 16 hours, 18 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 hours, 48 hours after surgery

07

Study locations

2 sites
  • Department of Spine Diseases and Pediatric Orthopedics, University of Medical Sciences, Poznań, Poland
    Poznan, Wielkopolska 61-545, Poland
  • Poznan Univesity of Medical Sciences
    Poznan, Wielkopolska 61-701, Poland
08

References and documents

Publications

  • Reysner T, Ciftci B, Pietraszek P, Purat T, Shadi M, Musielak B, Idzior M, Daroszewski P, Reysner M. Effect of intravenous dexamethasone on duration of analgesia following popliteal nerve block in pediatric ankle surgery: A randomized, triple-blinded clinical trial. J Clin Anesth. 2026 Feb;109:112094. doi: 10.1016/j.jclinane.2025.112094. Epub 2025 Dec 5. PubMed 41352236 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jun 2025, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
Jun 5, 2023
StartActual
Oct 17, 2023
Primary completionActual
Jun 30, 2025
CompletionActual
Jul 29, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05887765
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Oct 17, 2023
Primary completion
Jun 30, 2025
Completion
Jul 29, 2025
Last update
Sep 18, 2025

Study contacts

Tomasz Kotwicki, Prof.dr hab.
study chair · Poznań University of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Chloride

Start the discussion